SCHEMBL3520995

SCHEMBL3520995

N#Cc1c(N)nc2ccccc2c1NCc1ccco1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.54
MEN1 O00255 5/20 0.54
LMNA P02545 5/20 0.54
HTT P42858 4/20 0.54
PDE5A O76074 1/20 0.49
REN P00797 1/20 0.49
ALDH1A1 P00352 8/20 0.48
MAPT P10636 6/20 0.48
NPSR1 Q6W5P4 4/20 0.48
POLB P06746 2/20 0.48
KDM4E B2RXH2 7/20 0.47
HPGD P15428 3/20 0.47
HSD17B10 Q99714 3/20 0.47
GAA P10253 2/20 0.47
CASP1 P29466 2/20 0.47
CASP7 P55210 2/20 0.47
GLA P06280 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL939815 0.83 ADRA2A (0.44) KMT2AMEN1LMNAHTTALDH1A1
SCHEMBL3518003 0.82 KMT2A (0.65) KMT2AMEN1LMNAHTTPDE5A
SCHEMBL3529460 0.79 KMT2A (0.50) KMT2AMEN1LMNAPDE5AALDH1A1
SCHEMBL6625684 0.78 MEN1 (0.45) KMT2AMEN1LMNAHTTPDE5A
SCHEMBL6478801 0.78 ADORA3 (0.49) KMT2AMEN1LMNAHTTPDE5A
SCHEMBL5224155 0.77 KMT2A (0.45) KMT2AMEN1LMNAHTTPDE5A
SCHEMBL6671087 0.75 SMN1; SMN2 (0.40) KMT2AMEN1LMNAHTTPDE5A
SCHEMBL30315178 0.75 EGFR (0.47) KMT2AMEN1LMNAHTTALDH1A1
SCHEMBL6480157 0.74 KMT2A (0.53) KMT2AMEN1LMNAHTTPDE5A
SCHEMBL6487837 0.74 ADORA3 (0.47) KMT2AMEN1LMNAHTTPDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390349-B1 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI SA (FR) 2012-07-25 EP disclosed
US-7713992-B2 Triazolo-quinolin derivatives useful as adenosine receptor ligands SANOFI-AVENTIS (FR) 2010-05-11 US disclosed
US-7709489-B2 Imidazoquinoline derivatives as adenosine A3 receptor ligands SANOFI-AVENTIS (FR) 2010-05-04 US disclosed
US-20080255110-A1 IMIDAZOQUINOLINE DERIVATIVES AS ADENOSINE A3 RECEPTOR LIGANDS SANOFI-AVENTIS (FR) 2008-10-16 US disclosed
US-7419977-B2 Imidazoquinoline derivatives as adenosine A3 receptor ligands SANOFI-AVENTIS (FR) 2008-09-02 US disclosed
US-20080146604-A1 Triazolo-Quinolin Derivatives Useful as Adenosine Receptor Ligands SANOFI-AVENTIS (FR) 2008-06-19 US disclosed
US-7365089-B2 Triazolo-quinolin derivatives useful as adenosine receptor ligands SANOFI-AVENTIS (FR) 2008-04-29 US disclosed
EP-1560828-B9 IMIDAZOQUINOLINE DERIVATIVES AS ADENOSINE A3 RECEPTOR LIGANDS SANOFI AVENTIS (FR) 2007-02-14 EP disclosed
US-7176213-B2 Imidazoquinoline derivatives and their use as adenosine A3 ligands SANOFI-AVENTIS (FR) 2007-02-13 US disclosed
EP-1560828-B1 IMIDAZOQUINOLINE DERIVATIVES AS ADENOSINE A3 RECEPTOR LIGANDS SANOFI AVENTIS (FR) 2006-05-03 EP disclosed
US-20050070566-A1 Imidazoquinoline derivatives SANOFI-AVENTIS (FR) 2005-03-31 US disclosed
US-20040186133-A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands SANOFI (FR) 2004-09-23 US disclosed
EP-1456205-A1 IMIDAZOQUINOLINE DERIVATIVES Sanofi-Aventis (FR) 2004-09-15 EP disclosed
EP-1456204-A1 TRIAZOLO-QUINOLIN DERIVATIVES USEFUL AS ADENOSINE RECEPTOR LIGANDS Sanofi-Aventis (FR) 2004-09-15 EP disclosed
WO-2004046146-A1 IMIDAZOQUINOLINE DERIVATIVES AS ADENOSINE A3 RECEPTOR LIGANDS SANOFI-AVENTIS (FR) 2004-06-03 WO disclosed
EP-1390349-A1 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS Sanofi-Aventis (FR) 2004-02-25 EP disclosed
WO-2002096879-A9 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI SYNTHELABO (FR) 2003-11-20 WO disclosed
WO-2003053969-A1 IMIDAZOQUINOLINE DERIVATIVES SANOFI-SYNTHELABO (FR) 2003-07-03 WO disclosed
WO-2003053968-A1 TRIAZOLO-QUINOLIN DERIVATIVES USEFUL AS ADENOSINE RECEPTOR LIGANDS SANOFI-SYNTHELABO (FR) 2003-07-03 WO disclosed
WO-2002096879-A1 AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI-SYNTHELABO (FR) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070566-A1 Imidazoquinoline derivatives ADORA3, ADORA2A, ADORA1 KMT2A 3187/4885MEN1 2988/4885LMNA 2069/4885
US-20080146604-A1 Triazolo-Quinolin Derivatives Useful as Adenosine Receptor Ligands ADORA3, ADORA2A, ADORA1 KMT2A 3874/4885MEN1 3761/4885LMNA 2451/4885
US-20080255110-A1 IMIDAZOQUINOLINE DERIVATIVES AS ADENOSINE A3 RECEPTOR LIGANDS ADORA3, ADORA1, ADORA2A KMT2A 2710/4885MEN1 2389/4885LMNA 1966/4885
US-20040186133-A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands ADORA3, ADORA1, ADORA2A KMT2A 2739/4885MEN1 3078/4885LMNA 2918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.